HomeCompareNDCVF vs JNJ

NDCVF vs JNJ: Dividend Comparison 2026

NDCVF yields 13.11% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NDCVF wins by $17.1K in total portfolio value
10 years
NDCVF
NDCVF
● Live price
13.11%
Share price
$15.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.4K
Annual income
$2,963.65
Full NDCVF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NDCVF vs JNJ

📍 NDCVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNDCVFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NDCVF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NDCVF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NDCVF
Annual income on $10K today (after 15% tax)
$1,114.75/yr
After 10yr DRIP, annual income (after tax)
$2,519.10/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $1,466.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NDCVF + JNJ for your $10,000?

NDCVF: 50%JNJ: 50%
100% JNJ50/50100% NDCVF
Portfolio after 10yr
$38.8K
Annual income
$3,826.53/yr
Blended yield
9.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NDCVF
Analyst Ratings
2
Buy
3
Hold
1
Sell
Consensus: Hold
Altman Z
7.4
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NDCVF buys
0
JNJ buys
0
No recent congressional trades found for NDCVF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNDCVFJNJ
Forward yield13.11%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$47.4K$30.3K
Annual income after 10y$2,963.65$4,689.40
Total dividends collected$21.1K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: NDCVF vs JNJ ($10,000, DRIP)

YearNDCVF PortfolioNDCVF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,011$1,311.48$10,592$272.30+$1.4KNDCVF
2$14,324$1,472.22$11,289$357.73+$3.0KNDCVF
3$16,968$1,640.86$12,123$472.89+$4.8KNDCVF
4$19,972$1,816.53$13,141$629.86+$6.8KNDCVF
5$23,369$1,998.27$14,408$846.81+$9.0KNDCVF
6$27,190$2,185.12$16,021$1,151.60+$11.2KNDCVF
7$31,469$2,376.08$18,122$1,588.22+$13.3KNDCVF
8$36,242$2,570.14$20,930$2,228.20+$15.3KNDCVF
9$41,545$2,766.31$24,792$3,191.91+$16.8KNDCVF
10$47,417$2,963.65$30,274$4,689.40+$17.1KNDCVF

NDCVF vs JNJ: Complete Analysis 2026

NDCVFStock

Nordic Semiconductor ASA, a fabless semiconductor company, designs, develops, markets, and sells integrated circuits and related solutions for short-and long-range wireless applications in Europe, the Americas, and the Asia/Pacific. It offers ultra-low power components; and develops low power cellular IoT. The company also provides Bluetooth 5 solutions; low power cellular devices for the IoT; and Bluetooth 5.1 solutions for direction finding applications. In addition, it offers Zigbee 3.0 IoT solutions; Thread solution for low-power devices; nRF9160 system-in-package; nRF52 and nRF51 series system-on-chips, as well as nRF591, nRF53, nRF52, and nRF51 series software development kits; ANT, a proprietary ultra-low power wireless solution for battery operated products; and application specific integrated circuits and related consulting services. Further, the company provides software for system development, communication stacks, and application layer software, as well as development tools for desktops. Its products are used in various applications, such as audio, automotive, beacon, computer peripherals, drug delivery, patient monitoring and alerts, smart home, healthcare, connected health and home, education, industrial automation, LED lighting, logistics/asset tracking, transportation, retail and payment, sports and fitness, toys and gaming, virtual reality and augmented reality products, wireless PC peripherals, mobile phone accessories, and consumer electronics, as well as wearables, including connected watches, jewelry, proximity tags, and smart clothes and apparels. The company was founded in 1983 and is headquartered in Trondheim, Norway.

Full NDCVF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NDCVF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NDCVF vs SCHDNDCVF vs JEPINDCVF vs ONDCVF vs KONDCVF vs MAINNDCVF vs ABBVNDCVF vs MRKNDCVF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.